AIMS: To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example. METHODS: Data from three studies including 115 human immunodeficiency virus-infected South African adults were used. Patients were on antiretroviral therapy regimens including 200 mg nevirapine twice daily and sampled at steady state. A development process was suggested, implemented in NONMEM7 and the final model evaluated with an external data set. RESULTS: A stepwise approach proved efficient. Model development started with the intensively sampled data. Data were added sequentially, using visual predictive checks for inspecting their compatibility with the existing model. Covariate exploration was carried out, and auxiliary regression models were designed for imputation of missing covariates. Nevirapine pharmacokinetics was described by a one-compartment model with absorption through two transit compartments. Body size was accounted for using allometric scaling. The model included a mixture of two subpopulations with different typical values of clearance, namely fast (3.12 l h(-1)) and slow metabolizers (1.45 l h(-1)), with 17% probability of belonging to the latter. Absorption displayed large between-occasion variability, and food slowed the absorption mean transit time from 0.6 to 2.5 h. Concomitant antitubercular treatment including rifampicin typically decreased bioavailability by 39%, with significant between-subject variability. Visual predictive checks of external validation data indicated good predictive performance. CONCLUSIONS: The development strategy succeeded in integrating data from different sources to produce a model with robust parameter estimates. This work paves the way for the creation of a nevirapine mega-model, including additional data from numerous diverse sources.
AIMS: To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example. METHODS: Data from three studies including 115 human immunodeficiency virus-infected South African adults were used. Patients were on antiretroviral therapy regimens including 200 mg nevirapine twice daily and sampled at steady state. A development process was suggested, implemented in NONMEM7 and the final model evaluated with an external data set. RESULTS: A stepwise approach proved efficient. Model development started with the intensively sampled data. Data were added sequentially, using visual predictive checks for inspecting their compatibility with the existing model. Covariate exploration was carried out, and auxiliary regression models were designed for imputation of missing covariates. Nevirapine pharmacokinetics was described by a one-compartment model with absorption through two transit compartments. Body size was accounted for using allometric scaling. The model included a mixture of two subpopulations with different typical values of clearance, namely fast (3.12 l h(-1)) and slow metabolizers (1.45 l h(-1)), with 17% probability of belonging to the latter. Absorption displayed large between-occasion variability, and food slowed the absorption mean transit time from 0.6 to 2.5 h. Concomitant antitubercular treatment including rifampicin typically decreased bioavailability by 39%, with significant between-subject variability. Visual predictive checks of external validation data indicated good predictive performance. CONCLUSIONS: The development strategy succeeded in integrating data from different sources to produce a model with robust parameter estimates. This work paves the way for the creation of a nevirapine mega-model, including additional data from numerous diverse sources.
Authors: M J Lamson; J P Sabo; T R MacGregor; J W Pav; L Rowland; A Hawi; M Cappola; P Robinson Journal: Biopharm Drug Dispos Date: 1999-09 Impact factor: 1.627
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes Journal: Antimicrob Agents Chemother Date: 2011-09-26 Impact factor: 5.191
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Phumla Z Sinxadi; Jan-Stefan van der Walt; Helen M McIlleron; Motasim Badri; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens Journal: AIDS Res Ther Date: 2010-07-14 Impact factor: 2.250
Authors: Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Jos H Beijnen Journal: Br J Clin Pharmacol Date: 2002-10 Impact factor: 4.335
Authors: Stein Schalkwijk; Rob Ter Heine; Angela Colbers; Edmund Capparelli; Brookie M Best; Tim R Cressey; Rick Greupink; Frans G M Russel; José Moltó; Mark Mirochnick; Mats O Karlsson; David M Burger Journal: J Antimicrob Chemother Date: 2019-05-01 Impact factor: 5.790
Authors: Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; A Sarah Walker; Andrew Owen; Diana M Gibb; David Burger; Helen McIlleron; Paolo Denti Journal: J Antimicrob Chemother Date: 2016-10-05 Impact factor: 5.790
Authors: Miné de Kock; Joel Tarning; Lesley Workman; Elizabeth N Allen; Mamadou M Tekete; Abdoulaye A Djimde; David J Bell; Steve A Ward; Karen I Barnes; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Stijn W van Beek; Rob Ter Heine; Jan-Willem C Alffenaar; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson Journal: Clin Pharmacokinet Date: 2021-02-22 Impact factor: 6.447
Authors: Tjokosela Tikiso; Helen McIlleron; David Burger; Diana Gibb; Helena Rabie; Janice Lee; Marc Lallemant; Mark F Cotton; Moherndran Archary; Stefanie Hennig; Paolo Denti Journal: Br J Clin Pharmacol Date: 2021-08-12 Impact factor: 3.716
Authors: Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Adeniyi Olagunju; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Andrew Owen; A Sarah Walker; Diana M Gibb; Helen McIlleron; David Burger; Paolo Denti Journal: Br J Clin Pharmacol Date: 2016-04-25 Impact factor: 4.335
Authors: Ali Mohamed Ali; Melissa A Penny; Thomas A Smith; Lesley Workman; Philip Sasi; George O Adjei; Francesca Aweeka; Jean-René Kiechel; Vincent Jullien; Marcus J Rijken; Rose McGready; Julia Mwesigwa; Kim Kristensen; Kasia Stepniewska; Joel Tarning; Karen I Barnes; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191